Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetrahydrobiopterin (BH4) is an essential naturally occurring cofactor for several enzymes, including the three isoforms of nitric oxide synthase (NOS), phenylalanine hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase. In the context of cardiovascular research at The University of Texas at Arlington, BH4 is being studied for its role in endothelial function and its potential to mitigate oxidative stress-induced vascular impairment. BH4 is a critical regulator of endothelial nitric oxide synthase (eNOS) coupling; a deficiency or oxidation of BH4 leads to eNOS uncoupling, where the enzyme produces reactive oxygen species like superoxide instead of the vasodilator nitric oxide. This mechanism is hypothesized to contribute to the impaired skin blood flow and increased cardiovascular risk observed in certain populations, such as African Americans. The UTA study (NCT04154306) utilizes local BH4 supplementation via intradermal microdialysis to investigate whether restoring BH4 levels can improve microvascular function and reduce oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetrahydrobiopterin.